Anne Marie Liles, Anastasia B Jenkins, Hayden Hendrix, Emily Johnson, Hillary Rowe, Katie S McClendon
Journal: Nephrology nursing journal : journal of the American Nephrology Nurses' Association 2021;48(3):267-273
PMID: 34286938
Nutritional and metabolic abnormalities, or protein energy wasting, is a common complication of chronic kidney disease, leading to significant morbidity and mortality. The cause of these abnormalities is multifactorial, and therefore, difficult to treat. The International Society of Renal Nutrition and Metabolism suggests appetite stimulants, including megestrol, dronabinol, mirtazapine, and cyproheptadine, as adjunctive treatment options in addition to parenteral or oral nutritional supplementation. This article reviews the evidence for use of these drugs as appetite stimulants and discusses their use in patients with chronic kidney disease.
Copyright© by the American Nephrology Nurses Association.
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.